Enrolling by invitationPhase 3NCT03584165
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
Studying Choroideremia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NightstaRx Ltd, a Biogen Company
- Principal Investigator
- Medical DirectorBiogen
- Intervention
- BIIB111(genetic)
- Enrollment
- 330 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2018 – 2026
Study locations (25)
- UCLA - Jules Stein Eye Institute, Los Angeles, California, United States
- Vitreo Retinal Associates PA - The Millennium Center, Gainesville, Florida, United States
- University of Miami, Miami, Florida, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- MEEI Massachusets Eye and Ear Infirmary, Boston, Massachusetts, United States
- Columbia University Medical Center, New York, New York, United States
- Cincinnati Eye Institute - Blue Ash, Cincinnati, Ohio, United States
- OHSU - Casey Eye Institute, Portland, Oregon, United States
- Retina Foundation of the Southwest, Dallas, Texas, United States
- University of Wisconsin School of Medicine, Madison, Wisconsin, United States
- Instituto Genetica Ocular, São Paulo, Brazil
- The Northern Alberta Clinical Trials and Research Centre, Edmonton, Alberta, Canada
- The University of British Columbia - Eye Care Centre, Vancouver, British Columbia, Canada
- McGill University Health Centre, Montreal, Quebec, Canada
- Rigshospitalet-Glostrup, Oejenafdelingen, Glostrup Municipality, Denmark
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03584165 on ClinicalTrials.govOther trials for Choroideremia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1NCT06460844Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)Ray Therapeutics, Inc.
- RECRUITINGNCT06375239Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal DegenerationRay Therapeutics, Inc.
- ENROLLING BY INVITATIONNCT05158049Longitudinal Study of a Bionic EyeCenter for Eye Research Australia
- ACTIVE NOT RECRUITINGPHASE1NCT04483440Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia4D Molecular Therapeutics
- RECRUITINGNCT01866371High Resolution Retinal ImagingUniversity of Pennsylvania